SCTIMST’s Cholederm Wound Treatment Enters the Market

SCTIMST’s Cholederm Wound Treatment Enters the Market

Cholederm, a treatment for chronic wounds and non-malignant burns developed by the Sree Chitra Tirunal Institute for Medical Sciences and Technology (SCTIMST) in Thiruvananthapuram, Kerala, formally entered the market in January 2026.

Product and regulatory approval

Cholederm is manufactured from an acellular matrix derived from the gallbladders of farm animals. SCTIMST describes it as the world’s first tissue graft scaffold of animal origin for accelerated wound healing. The Central Drugs Standard Control Organisation (CDSCO) approved it as a Class D medical device in 2023.

Technology transfer and marketing

SCTIMST transferred the technology in 2017 to Alicon Medical Private Limited, a startup incubated at the institute’s Technology Incubation and Medical Entrepreneurship Development (TIMED) centre. Alicon Medical is responsible for marketing Cholederm. Reports placed its price in the range of ₹10,000–₹30,000.

Important Facts for Exams

  • Acellular scaffold: Acellular tissue scaffolds retain the extracellular matrix after resident cells are removed; the matrix can support artificial-organ and tissue regeneration.
  • Skin-graft support: In skin-graft applications, decellularised matrices mechanically support damaged tissue while encouraging the development of connective tissue from the host.
  • Class-based licensing: Under India’s Medical Devices Rules, 2017, the Central Licensing Authority handles manufacture licences for Class C and D devices, while state authorities license Class A and B.
  • Institute status: SCTIMST is an autonomous institute under India’s Department of Science and Technology and holds Institute of National Importance status.
Originally written on January 23, 2026 and last modified on November 19, 2026.
Tags: , , , , ,

Leave a Reply

Your email address will not be published. Required fields are marked *